文献リスト

1) Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979; 301: 61-8

2) Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implan­tation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331: 489-95

3) Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-23

4) Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104: 2007-11

5) McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519-21

6) Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115: 1440-55; discussion 1455

7) Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discon­tinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48: 2584-91

8) Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombo­sis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126-30

9) Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007; 356: 1009-19

10) Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 1030-9

11) Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356: 998-1008

12) King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008; 51: 172-209

13) King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Asso­ciation Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Commit­tee. Circulation. 2008; 117: 261-95

14) Farb A, Kolodgie FD, Hwang JY, et al. Extra­cellular matrix changes in stented human coro­nary arteries. Circulation. 2004; 110: 940-7

15) Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996; 334: 561-6

16) Ramcharitar S, Garcia-Garcia H, Nakazawa G, et al. Ultrasonic and pathological evidence of a neo-intimal plaque rupture in patients with bare metal stents. Eurointervention. 2007; 3: 290-1

17) de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis Trials. Curr Interv Cardiol Rep. 2000; 2: 326-31

18) Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by tar­geting regulators of the cell cycle. Circulation. 1999; 99: 2164-70

19) Kay IP, Wardeh AJ, Kozuma K, et al. Radioactive stents delay but do not prevent in-stent neo­intimal hyperplasia. Circulation. 2001; 103: 14-7

20) Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000; 36: 2325-32

21) Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001; 104: 473-9

22) Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal forma­tion in a porcine coronary model. Circulation. 2001; 104: 1188-93

23) Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005; 112: 270-8

24) Guagliumi G, Farb A, Musumeci G, et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation. 2003; 107: 1340-1

25) Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48: 193-202

26) Finn AV, Joner M, Nakazawa G, et al. Patho­logical correlates of late drug-eluting stent throm­bosis: strut coverage as a marker of endothelial­ization. Circulation. 2007; 115: 2435-41

27) Gonzalo N, Barlis P, Serruys PW, et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina: insights from optical coherence tomography. JACC Cardiovasc Interv. 2009; 2: 445-52

28) Suzuki Y, Ikeno F, Koizumi T, et al. In vivo comparison between optical coherence tomo­graphy and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv. 2008; 1: 168-73

29) Kubo T, Imanishi T, Kitabata H, et al. Com­parison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study. JACC Cardiovasc Imaging. 2008; 1: 475-84

30) Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001; 104: 600-5

31) Takebayashi H, Mintz GS, Carlier SG, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2004; 110: 3430-4

32) Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent throm­bosis at culprit sites after drug-eluting stent place­ment for acute myocardial infarction patients: an autopsy study. Circulation. 2008; 118: 1138-45

33) Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006; 355: 1105-13

34) Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocar­dial infarction. N Engl J Med. 2006; 355: 1093-104

35) Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarc­tion. N Engl J Med. 2008; 359: 1330-42

36) Steg PG, Fox KA, Eagle KA, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J. 2009; 30: 321-9

37) Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious？ Circulation. 2004; 109: 701-5

38) Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000; 356: 1895-7

39) Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009; 120: 141-9, 1-2

40) Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47: 175-81

41) Ako J, Morino Y, Honda Y, et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol. 2005; 46: 1002-5

42) Awata M, Nanto S, Uematsu M, et al. Hetero­geneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. JACC Cardiovasc Interv. 2009; 2: 453-8

43) Nakazawa G, Finn AV, John MC, et al. The significance of preclinical evaluation of siro­limus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol. 2007; 100: 36M-44M

44) Nakazawa G, Finn AV, Ladich E, et al. Drug-eluting stent safety: findings from preclinical studies. Expert Rev Cardiovasc Ther. 2008; 6: 1379-91

45) Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008; 52: 333-42

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp